Global Longlife Hospital appoints Hiren Mandaliya as Independent Director
Global Longlife Hospital and Research Ltd announced the appointment of Hiren Mandaliya as a Non-Executive Independent Director for a five-year term from March 31, 2026, to March 30, 2031. The appointment was approved by shareholders at the Annual General Meeting on June 25, 2026. Mandaliya, a Chartered Accountant, brings expertise in accounting and taxation.

*this image is generated using AI for illustrative purposes only.
Global Longlife Hospital and Research Ltd has appointed Hiren Mandaliya as a Non-Executive Independent Director for a period of five years. The appointment, effective from March 31, 2026, to March 30, 2031, was approved by shareholders at the Annual General Meeting held on June 25, 2026, based on the recommendation of the Board of Directors.
Mandaliya is a qualified Chartered Accountant with expertise in accounting, taxation, compliances, finalization of accounts, filing of returns, assessment proceedings, and representation before tax authorities. The disclosure confirms that he is not related to any director of the company and is not debarred from holding the position of director by any SEBI order or other authority.
The appointment was disclosed to the BSE under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company provided the necessary details in accordance with Schedule III of the SEBI LODR Regulations and the relevant SEBI Master Circular.
Appointment Details
| Detail | Information |
|---|---|
| Name of Director | Mr. Hiren Mandaliya |
| DIN | 11636452 |
| Designation | Non-Executive Independent Director |
| Date of Appointment | June 25, 2026 |
| Term of Office | Five Years (March 31, 2026 to March 30, 2031) |
| Qualification | Chartered Accountant |
Historical Stock Returns for Global Longlife Hospital & Research
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +3.86% | +15.56% | -4.56% | -49.39% | -52.48% | -91.66% |
How will Mr. Mandaliya's financial expertise influence the company's future fiscal strategies and cost management?
What specific governance improvements can shareholders expect following the addition of this independent director?
Does this appointment signal a shift in the company's focus towards stricter regulatory compliance and transparency?































